What In The World Is Going On With Benetic Biopharma (BNTC) Stock
Portfolio Pulse from Henry Khederian
Benetic Biopharma (BNTC) shares are up 46.35% after the company announced FDA clearance of the IND for BB-301, a gene therapy for Oculopharyngeal Muscular Dystrophy. This marks a significant advancement for both Benitec and patients with OPMD-related Dysphagia.
June 26, 2023 | 1:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BNTC shares rose 46.35% after FDA clearance of IND for BB-301, a gene therapy for Oculopharyngeal Muscular Dystrophy, marking a significant advancement for the company and patients.
The FDA clearance of the IND for BB-301 is a significant milestone for Benetic Biopharma, as it allows the company to proceed with clinical trials for the gene therapy. This positive news has led to a surge in BNTC's stock price, as investors anticipate potential success in treating Oculopharyngeal Muscular Dystrophy.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100